INTRODUCTION
The phosphoinositide 3-kinase (PI3K) pathway has key regulatory roles in cell survival, proliferation, and differentiation. 1 It is among the most frequently altered pathways in human cancers, and PI3K inhibitors are used to treat a variety of malignancies. 1 Class I PI3K, the best studied of the PI3K classes, is a heterodimer with both regulatory and catalytic subunits, the latter of which exists in 4 distinct isoforms (a, b, g, and d). 2 The a and b isoforms are expressed ubiquitously, but g and d isoform expression is mainly found on leukocytes and cells of the adaptive immune system.
2 PI3K inhibitors include pan-class I PI3K inhibitors, isoform-specific class I PI3K inhibitors, and dual PI3K-mechanistic target of rapamycin (mTOR) inhibitors. Dermatologic toxicities in patients on PI3K inhibitors have not been characterized to date. We report on 4 patients on PI3K inhibitors who had psoriasiform cutaneous eruptions.
REPORT OF CASES
A 59-year-old man with chronic lymphocytic leukemia (CLL) and progressive disease 24 months after completing 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) was initiated on the combination of ibrutinib and a targeted p110d inhibitor. About 3 months after starting therapy, a solitary, scaling, nonpruritic plaque developed on his right leg. Fifteen months after starting therapy, he suffered a blistering sunburn. Within 2 weeks, a new, red, scaling rash developed in the distribution of the burn on his arms and legs that subsequently generalized to the trunk. He had no personal or family history of psoriasis. At the time of presentation to the dermatology clinic, he had psoriasiform, erythematous, well-demarcated papules, and large plaques on his shoulders, arms, and bilateral lower extremities in a strikingly photo-distributed pattern (Fig 1, A and B) . Punch biopsy of the left thigh found psoriasiform epidermal hyperplasia with mild spongiosis, confluent parakeratosis, and intraepidermal as well as intracorneal neutrophils with rare eosinophils (Fig  2, A) . Both ibrutinib and the p110d inhibitor were held; the patient was started on triamcinolone 0.1% cream twice daily to the trunk and extremities. The eruption continued to spread to involve the face, scalp, back, chest, and soles. The patient then started acitretin, 10 mg daily, with clobetasol 0.05% ointment twice daily to affected areas on the trunk, and desonide 0.05% cream to affected areas on the face. Photoprotective behaviors were strictly enforced. His psoriasis improved significantly, and both drugs were restarted without incident. The patient had a complete response to the CLL treatment. Cases 2 through 4 are presented in Table I .
DISCUSSION
PI3K inhibitors are a relatively novel class of small molecule inhibitors currently approved for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma; they are also under investigation for the treatment of a variety of solid tumors.
1 PI3K inhibitors are unique drugs in that their mechanism of action, depending on isoform(s) targeted, ranges from direct inhibition of the PI3K pathway to indirect anticancer effects such as inhibiting angiogenesis, disrupting interactions between cancer cells and tumor stroma, and (Fig 1, A) . Spread to involve face, scalp, trunk, gluteal cleft, and soles (Fig 1, B) . (Fig 1, C ) , nail pitting and oil spots (Fig 1, D enhancing effector T-cell responses. 3 Although cutaneous eruptions secondary to PI3K inhibitors have been reported in up to 58% of patients on selective p110d inhibitors and 27% of patients on pan-PI3K inhibitors, these eruptions have not been further characterized to date. 4, 5 We report on 4 patients with psoriasiform eruptions arising 15 days to 17 months after starting a PI3K inhibitor. The patient who had a psoriasiform eruption at the shortest interval after exposure to a PI3K inhibitor had a previous history of psoriasis. Although we cannot definitively prove that the PI3K inhibitors were the cause of the eruptions, 2 patients had clear improvement with dose reduction, and 1 eruption resolved entirely after discontinuing the PI3K inhibitor. Fludarabine, cyclophosphamide, rituximab, and ibrutinib, the concomitantly exposed drugs in our patients, have not been associated with psoriasiform dermatitis, despite their common use in leukemia treatment. In the patient with Koebnerization after a sunburn, the photosensitivity itself was ultimately attributed to the patient also taking ibrutinib, which is known to inhibit epidermal growth factor receptor. 6 Epidermal growth factor receptor inhibitoreassociated photosensitivity has been well described in the literature, and PI3K inhibitors have not been associated with photosensitivity to date. 7, 8 It is notable that IL-22, a cytokine known to contribute to the pathogenesis of psoriasis, has been found to be upregulated by PI3K pathway activation. [9] [10] [11] Further, both p110d and p110g inhibitors have been found to reduce IL-17 production from peripheral blood monocytic cells of psoriatic or healthy donors. 12 It is therefore hypothesized that PI3K inhibitors may actually treat inflammatory skin disorders. These in vitro studies, however, do not take into account the global immunologic effects of PI3K inhibition. In particular, p110d blockade inhibits regulatory T cells, promoting antitumor effector CD8
1 T cells. 13 Side effects of p110d inhibitors include colitis, pneumonitis, and hepatitis associated with increased CD8
1 T-cell infiltrates, decreased circulating regulatory T cells, and improvement with corticosteroids. 4, 14, 15 Global p110d inhibition may result in worsening or new autoinflammatory skin disorders such as psoriasis caused by unregulated, nonspecific T-cell activation.
Given the clinical findings in our patients, typical psoriasis therapies were instituted for treatment. Three of 4 patients were able to successfully control cutaneous symptoms with topical treatments alone; 1 patient did well with the addition of oral acitretin. Two patients continued on dose-reduced PI3K inhibitor therapy with good response. In keeping with the psoriasis-specific therapeutic ladder, we suggest first-line skin-directed therapy for psoriasiform cutaneous toxicities with topical steroids, calcineurin inhibitors, retinoids, and vitamin D analogs. If cutaneous findings are extensive, narrow-band ultraviolet B may be trialed, given its efficacy in psoriasis, with careful consideration taken to avoid concomitant photosensitizing medications. For refractory disease, acitretin, apremilast, and methotrexate are all systemic therapies that can be considered as adjuncts in the appropriate patient.
Despite the recommendation for the use of prednisone for eruptions involving greater than 30% body surface area in many clinical trials, except in very rare cases of erythroderma, systemic steroids are not part of the management algorithm for psoriasis. These cases emphasize the importance of early dermatologic evaluation to specifically classify the clinical features of cutaneous toxicities to PI3K inhibitors. With rapid institution of appropriate, targeted therapies, patients will hopefully be able to maintain a high quality of life and remain on lifeprolonging therapies.
